BioInvent International AB

www.bioinvent.com

BioInvent International AB is a research-based pharmaceutical company focused on the discovery and development of innovative antibody-based drugs against cancer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

news image

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

MedTech, Industrial Impact

BIO-TECHNE AND CST PARTNER TO VALIDATE SIMPLE WESTERN ANTIBODIES

Bio-Techne | February 15, 2023

news image

On February 14, 2023, Bio-Techne Corporation and Cell Signaling Technology (CST) announced that CST antibodies now have Simple Western™ validation. This will make it easier for researchers from numerous disciplines to study essential molecular signaling pathways on a reliable and validated platform. Accurate data must be obtained quickly and efficiently in order to advance drug discovery and development. This continued collaboration will provide a broader menu of Simple We...

Read More

Medical

HISTOSONICS ANNOUNCES AGREEMENT WITH GE HEALTHCARE

HistoSonics | May 24, 2022

news image

HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare's LOGIQ E10 Series ultrasound imaging platform to power the real time visualization features of HistoSonics' novel sonic beam therapy. As part of the agreement and upon market authorization, HistoSonics will distribute GE Healthcare's LOGIQ E10 Series on a one-to-one basis with its breakthrough liver th...

Read More

Medical

ASEP MEDICAL HOLDINGS INC. ANNOUNCES ADDITIONAL LISTING TO THE OTCQB VENTURE MARKET IN THE U.S.

SEPSIS | April 25, 2022

news image

Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce its recent successful listing on the OTCQB Venture Market in the US. The Company will be trading under the stock symbolOTCQB: SEPSF and will continue to sell its common shares on the CSE under the stock symbol CSE: ASEP. Asep Inc. will officially commence trading on the OTCQB as of the market opening today. The Company is also pleased to announce that it ...

Read More
news image

Industrial Impact

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

news image

MedTech, Industrial Impact

BIO-TECHNE AND CST PARTNER TO VALIDATE SIMPLE WESTERN ANTIBODIES

Bio-Techne | February 15, 2023

On February 14, 2023, Bio-Techne Corporation and Cell Signaling Technology (CST) announced that CST antibodies now have Simple Western™ validation. This will make it easier for researchers from numerous disciplines to study essential molecular signaling pathways on a reliable and validated platform. Accurate data must be obtained quickly and efficiently in order to advance drug discovery and development. This continued collaboration will provide a broader menu of Simple We...

Read More
news image

Medical

HISTOSONICS ANNOUNCES AGREEMENT WITH GE HEALTHCARE

HistoSonics | May 24, 2022

HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare's LOGIQ E10 Series ultrasound imaging platform to power the real time visualization features of HistoSonics' novel sonic beam therapy. As part of the agreement and upon market authorization, HistoSonics will distribute GE Healthcare's LOGIQ E10 Series on a one-to-one basis with its breakthrough liver th...

Read More
news image

Medical

ASEP MEDICAL HOLDINGS INC. ANNOUNCES ADDITIONAL LISTING TO THE OTCQB VENTURE MARKET IN THE U.S.

SEPSIS | April 25, 2022

Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce its recent successful listing on the OTCQB Venture Market in the US. The Company will be trading under the stock symbolOTCQB: SEPSF and will continue to sell its common shares on the CSE under the stock symbol CSE: ASEP. Asep Inc. will officially commence trading on the OTCQB as of the market opening today. The Company is also pleased to announce that it ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us